The best GLP-1 telehealth providers of 2026
Five platforms worth comparing — bmiMD, Henry Meds, Hims, ShedRX, and Levity — head-to-head on Semaglutide and Tirzepatide pricing, compounded vs branded supply, physician oversight, state availability, and money-back policy. The shortlist for buyers ready for medical-grade weight intervention without paying $1,000+/mo for branded retail.
Editor's pick: bmiMD
For value-tier buyers ready to start a compounded GLP-1 protocol with included physician oversight, bmiMD is the conservative-correct pick in 2026. Compounded Semaglutide starts at $289/month ($379.99 in CA and NC) and Tirzepatide runs $349 (micro-dose) to $399 (full dose) — competitive with the lowest credible pricing in the category, with the all-in subscription bundling physician consultations, titration support, and medication delivery. The platform is Awin-backed at the affiliate layer, transparently flags state-by-state pricing variation upfront, and offers a 100% money-back guarantee if you fail the telehealth eligibility evaluation. Henry Meds is the more established ecosystem with longer operational track record; bmiMD is the better entry economics for buyers without prior platform commitment.
Best ecosystem maturity: Henry Meds (Semaglutide $297/mo, Tirzepatide $449/mo) — longer track record, deeper operational scale, telehealth provider visits and shipping all bundled. The right pick if brand maturity matters more than the $50-100 monthly delta.
Best for branded retail-grade access: Hims (branded Wegovy $299/mo injectable, oral $249/mo; Zepbound $399/mo) — largest consumer brand in the category, but compounded Semaglutide is winding down for new patients post-March 2026 Novo Nordisk settlement. The right pick if you want branded supply with telehealth convenience.
Best for tirzepatide-specific value: ShedRX (Tirzepatide from $199/mo entry, $275-375/mo standard) — multiple delivery formats including sublingual drops and lozenges for buyers who prefer non-injectable. Optional $70/mo coaching upgrade.
Best for lowest-friction Semaglutide start: Levity (compounded Semaglutide $175-225/mo) — the lowest entry pricing for compounded Semaglutide in this guide, with HSA/FSA accepted. No compounded Tirzepatide; branded Mounjaro at retail pricing only.
Skip if: your BMI is under 27 with no metabolic risk factors, you are pregnant or planning pregnancy, you have a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome, or your insurance already covers branded Wegovy or Zepbound (run that through insurance instead).
Why GLP-1 telehealth became a longevity-medicine category
GLP-1 receptor agonists started as type-2 diabetes drugs in the late 2000s, expanded into FDA-approved obesity medications in 2014 (Saxenda) and 2021 (Wegovy), and have undergone a categorical re-evaluation in the 2024-2026 longevity-research wave. The papers from that period — cardiovascular outcomes in SELECT, kidney outcomes in FLOW, cognitive signals in EVOKE, and inflammation markers across multiple smaller trials — moved the medical-academic frame from “weight-loss drug” to “metabolic-aging intervention with weight-loss as one of several effects.” That re-frame is what brought longevity buyers into the category.
The pricing gap between branded retail and compounded telehealth supply is the second reason the category exploded. Branded Wegovy and Zepbound run roughly $1,000-1,400/month at cash retail. Compounded Semaglutide through state-licensed pharmacies runs $175-300/month at the platforms in this guide — a 4-7x cost differential for the same active ingredient. That gap was created by the FDA shortage-list designation that began in 2022, which permitted 503A and 503B compounding pharmacies to produce GLP-1s in commercial volumes without going through the new-drug-approval pathway. The shortage was resolved in 2024-2025, and the regulatory ground beneath compounded supply has been narrowing since.
The 2026 landscape reflects that narrowing. Hims settled with Novo Nordisk in March 2026 and exited compounded Semaglutide for new patients, defaulting to branded retail going forward. Other platforms continue compounded supply but face the same regulatory pressure. The honest framing is that the cost-savings window for compounded GLP-1s is real but narrowing — buyers entering the category in 2026 should plan for the possibility of platform exits, supply restrictions, or pricing increases as the regulatory environment continues shifting.
The five platforms in this guide all operate on a cash-pay subscription model with physician oversight included in the monthly cost. The differentiation is in three places: (1) compounded vs branded sourcing (Hims is mostly branded going forward; the other four are mostly compounded), (2) molecule coverage (Levity does not offer compounded Tirzepatide; the other four cover both), and (3) delivery format (ShedRX offers sublingual drops and lozenges in addition to standard injection; the others are injection-only). Pricing variance within compounded Semaglutide ($175-300/mo) and within compounded Tirzepatide ($199-449/mo) reflects state regulations, partner-pharmacy economics, and what the platform bundles in (telehealth visits, shipping, coaching).
GLP-1s are medication, not a supplement — frame the bet accordingly
GLP-1s require medical oversight. They are prescription drugs with real efficacy data and real side-effect profiles, not over-the-counter supplements. Side effects in the first 4-8 weeks are real for most users — nausea (15-30%), constipation, diarrhea, fatigue, and GI distress are the headline issues, and they are unpleasant enough that a meaningful minority of users discontinue in the titration window before reaching maintenance dose. Less common but more serious risks include pancreatitis, gallbladder disease, kidney injury secondary to dehydration, and a hard contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome.
The long-term data is still accumulating. The 5+ year cohort outcomes that the longevity-medicine community wants — does GLP-1 use translate into longer healthspan, lower all-cause mortality, sustained metabolic benefit after discontinuation — are still being collected. The cardiovascular outcomes data (SELECT trial) is the most mature signal, and it is genuinely encouraging. The cognitive and inflammation signals are earlier-stage and less certain. Buyers should price in that what looks like a strong case in 2026 may look stronger or weaker in 2030 as longer-cohort data matures.
The right buyer mindset: this is medication, not a supplement, and the platforms in this guide are doing the prescribing. Their telehealth eligibility evaluation is the relevant clinical decision, not anything written in this guide. Buyers who go in with the “just sign me up” mindset that works for ordering an NMN supplement are setting themselves up for a worse outcome than buyers who treat this as a medical decision with the gravity it deserves. Read the medication guides, understand the side-effect profile, have a primary-care relationship outside the telehealth platform that knows you are on a GLP-1, and have an exit plan if the side effects exceed your tolerance threshold.
The five contenders, compared
Pricing verified 2026-05-05 via brand sites and category trackers. State-by-state variation applies; check checkout for your state.
| Spec | bmiMD | Henry Meds | Hims | ShedRX | Levity |
|---|---|---|---|---|---|
| Semaglutide $/mo (lowest tier) | $289 ($379.99 in CA/NC) | $297 | $199 (6-mo plan); compounded winding down for new patients | $199 (entry); $295 standard dose | $175-225 (compounded) |
| Tirzepatide $/mo (lowest tier) | $349 (micro) / $399 (full) | $449 | Branded Zepbound $399; compounded discontinued | $199 (entry) / $275-375 standard | Branded Mounjaro $1,249-1,299 only (no compounded) |
| Compounded vs branded | Compounded (503A/503B partner pharmacies) | Compounded | Branded retail (compounded exited Mar 2026) | Compounded | Compounded Semaglutide; Branded Tirzepatide |
| Physician oversight model | MD consultation included; titration support | Telehealth provider; medication management included | Licensed clinician via app | Telehealth provider; optional 1:1 coaching $70/mo | Clinical consultation + unlimited support included |
| Cancellation / money-back | 100% money-back if not eligible after telehealth eval | Cancel anytime; standard refund policies | Cancel anytime; subscription-based | Cancel anytime; no compounded subscription fee | Cancel anytime; HSA/FSA accepted |
| State availability | Most US states; CA/NC at higher pricing | Most US states | Most US states (branded coverage broader) | Most US states | Most US states |
| FSA/HSA accepted | Yes | Yes | Yes | Yes | Yes |
| Editor's score | 8.5 / 10 | 8.4 / 10 | 7.9 / 10 (post-compounded exit) | 8.1 / 10 | 7.8 / 10 |
The five GLP-1 telehealth platforms that actually deserve consideration
bmiMD — The value-tier compounded GLP-1 platform with included physician oversight
Semaglutide from $289/mo (CA/NC $379.99); Tirzepatide $349 micro / $399 full · Compounded via 503A/503B partner pharmacies · MD consultation + titration support included · 100% money-back guarantee if not eligible · FSA/HSA accepted · 30-day affiliate cookie window
bmiMD entered the GLP-1 telehealth category in 2023 with a clear positioning: same Semaglutide and Tirzepatide compounds available through the established names (Henry Meds, Hims, ShedRX), priced competitively at $289/month entry for Semaglutide and $349-399 for Tirzepatide, with the all-in subscription bundling physician consultations and titration support. The platform is transparent about state-by-state pricing variation — California and North Carolina pay $379.99/month for Semaglutide vs $289 elsewhere, and that pricing is surfaced in checkout rather than buried in fine print.
What bmiMD does well: the pricing is competitive without being the absolute floor (Levity beats it on compounded Semaglutide entry pricing, but does not offer compounded Tirzepatide), the physician oversight model is real with included consultations and titration adjustment, the 100% money-back guarantee for buyers who fail the eligibility evaluation removes the “sign up and find out” risk, and the platform handles FSA/HSA reimbursement straightforwardly. The Awin affiliate program is operationally mature with a $50 CPA per signup and a 30-day cookie window — Lifespan Vault has an active affiliate relationship with bmiMD, and the link below is tracked through Awin.
Where bmiMD loses ground: shorter operational track record than Henry Meds (3 years vs 5+), smaller community footprint and editorial coverage, and the state-pricing variance can push the math closer to branded retail in CA/NC than the headline pricing suggests. For buyers in those higher-pricing states, the math may favor running insurance through primary care for branded supply instead. For buyers elsewhere, bmiMD is the conservative-correct entry point at the value-tier compounded price.
Henry Meds — The established compounded telehealth platform
Semaglutide $297/mo; Tirzepatide $449/mo · Compounded · Telehealth provider visits, medication management, and shipping all bundled · 5+ year operational track record · FSA/HSA accepted
Henry Meds is the longest-running compounded GLP-1 platform in the category. The brand started as a broader telehealth provider covering hormone optimization, sexual health, and other prescribing categories, and added GLP-1s as the category exploded in 2022-2023. The operational track record is real — 5+ years of compounded-supply experience, larger pharmacy partner network, deeper editorial coverage, and a brand-recognition footprint that comes with being one of the first credible names in the category.
The pricing sits in the middle of the value-tier compounded range: Semaglutide at $297/month is $8 above bmiMD's entry pricing and meaningfully cheaper than Hims branded retail; Tirzepatide at $449/month is the highest of the compounded providers in this guide ($50 above bmiMD's $399 full-dose pricing, $74-150 above ShedRX's $275-375 standard range). The all-in monthly fee bundles telehealth provider visits, medication, and shipping, which simplifies the math vs platforms that surcharge for individual components.
Where Henry Meds wins: the operational maturity is genuinely valuable for buyers who weight track record over a $10-50 monthly delta. The platform has been around longer than the FDA shortage-list compounded-supply window, weathered the 2024-2025 regulatory shifts, and has the partner-pharmacy infrastructure to keep operating through whatever 2026-2027 regulatory changes come next. For buyers prioritizing “will this platform still exist in 18 months,” Henry Meds is the safer pick. The trade-off: the Tirzepatide pricing is meaningfully above the lowest credible options, which matters more for buyers stepping up from Semaglutide than for buyers starting fresh.
Hims (weight loss) — The brand-name access path
Branded Wegovy $299/mo injectable, $249/mo oral; branded Zepbound $399/mo; oral Semaglutide pill from $49 first month introductory · Compounded Semaglutide winding down for new patients post-March 2026 Novo Nordisk settlement · Largest brand recognition in the consumer telehealth category · FSA/HSA accepted
Hims is the largest consumer-telehealth brand in the United States and the most-recognized name in the GLP-1 category by paid-acquisition footprint. The brand operated in compounded Semaglutide for 2-3 years and built meaningful market share — but in March 2026, Hims settled with Novo Nordisk and exited compounded Semaglutide for new patients. The platform now defaults new GLP-1 patients to branded Wegovy, with an oral Semaglutide pill option (introductory pricing $49 first month) and Zepbound for Tirzepatide.
What Hims does well post-settlement: the brand recognition is real, the user experience for booking visits and managing prescriptions is the most polished in the category, and the partnership with Novo Nordisk gives them direct access to branded Wegovy at retail-competitive pricing ($299/month for injectable Wegovy is meaningfully cheaper than uncoordinated cash retail at $1,000+/month). The oral Semaglutide pill option ($49 first month introductory, then standard branded pricing) is unique in the category and is the only oral branded-Semaglutide path most buyers have access to.
Where Hims loses to the compounded competitors: the pricing for branded Wegovy at $299/month is meaningfully above bmiMD's $289 compounded Semaglutide and Levity's $175-225 compounded range, and the Zepbound branded Tirzepatide at $399 is roughly comparable to bmiMD's $399 full-dose compounded but above ShedRX's $275-375 standard range. For buyers who weight branded sourcing and quality control above the compounded value play, Hims is now the right pick. For buyers cost-anchored to the compounded discount, Hims is no longer competitive on the Semaglutide side.
ShedRX — The multi-format compounded specialist
Semaglutide from $199 entry, $295 standard; Tirzepatide from $199 entry, $275-375 standard; Sublingual drops from $229; Lozenges from $199 · Compounded · Optional 1:1 coaching $70/mo · No subscription fee on compounded · FSA/HSA accepted
ShedRX differentiates on delivery-format diversity. Where the other platforms in this guide are injection-only or injection-plus-occasional-oral, ShedRX runs four formats: standard weekly injections, sublingual drops (daily, absorbed under the tongue), and lozenges (daily, dissolvable). For buyers with needle aversion or for whom weekly injections create compliance friction, the non-injectable options are genuinely useful — and at $199-229/month entry pricing, they are competitive with the lowest credible compounded Semaglutide pricing in the category.
The Tirzepatide pricing is where ShedRX earns specific consideration: $275-375/month for standard-dose compounded Tirzepatide is below bmiMD's $349-399 range and meaningfully below Henry Meds' $449 single-tier pricing. For buyers stepping up from Semaglutide to Tirzepatide or starting directly on Tirzepatide, ShedRX is the value-tier pick. The optional $70/month coaching upgrade is reasonable for buyers who want the accountability layer that Hims and Henry Meds bundle in by default — and unlike the bundled providers, ShedRX lets you skip it if you have a coaching or behavior-change relationship elsewhere.
Where ShedRX loses ground: the brand is newer than Henry Meds and Hims, the editorial coverage is thinner, and the bioavailability evidence base for sublingual drops and lozenges is less mature than the standard injectable formulation. The active ingredient is the same, but absorption profile data on the non-injectable compounded formats is sparser than on the standard route. Buyers who want maximum confidence in dosing accuracy should default to the injectable form even at ShedRX. Buyers who weight compliance and convenience over the bioavailability uncertainty are the right fit for the sublingual or lozenge formats.
Levity — The lowest-entry compounded Semaglutide
Compounded Semaglutide $175-225/mo; Branded Mounjaro Tirzepatide $1,249-1,299/mo (no compounded Tirzepatide) · Clinical consultation + unlimited support included · Cancel anytime · FSA/HSA accepted · No insurance accepted
Levity offers the lowest entry pricing for compounded Semaglutide in this guide — $175-225/month depending on dose tier. That is below bmiMD's $289 entry, below Henry Meds' $297, below ShedRX's $295 standard, and meaningfully below Hims' current branded-only Wegovy at $299. For cost-sensitive buyers starting on Semaglutide who do not yet need to step up to Tirzepatide, Levity is the rational entry economics pick. The all-in monthly fee bundles clinical consultation, unlimited clinical support, and medication.
The structural caveat: Levity does not currently offer compounded Tirzepatide. Buyers who want Tirzepatide through Levity have to use branded Mounjaro at $1,249-1,299/month — pricing that is competitive with cash retail elsewhere but not with the compounded Tirzepatide options at bmiMD ($349-399), ShedRX ($275-375), or Henry Meds ($449). For buyers who anticipate stepping up to Tirzepatide, starting at Levity creates a platform-switching cost — you are not getting the benefit of the value-tier Tirzepatide pricing the other compounded providers offer.
Where Levity wins: the lowest-friction entry economics for compounded Semaglutide-first buyers. The right buyer profile is someone with a moderate weight-loss target (10-15% body weight), willing to start on Semaglutide and reassess at the 6-month mark, and not anchored to a need for Tirzepatide-specific access. Where Levity does not fit: buyers who anticipate needing the dual-mechanism Tirzepatide should pick a platform that covers both compounded molecules from day one to avoid the platform-switching tax.
Skip the category if…
- Your BMI is under 27 with no metabolic risk factors. The clinical-trial enrollment criteria for branded Wegovy and Zepbound center on BMI 30+ (or BMI 27+ with metabolic comorbidity). Buyers below that threshold without insulin resistance, prediabetes, hypertension, or other metabolic risk markers are unlikely to be approved by the platform's telehealth eligibility evaluation, and the off-label use case is meaningfully weaker on the risk-benefit math. The protocol that fits this buyer profile better is foundational metabolic work — diet quality, exercise volume, sleep, stress reduction — which has stronger evidence per dollar than off-label GLP-1 supplementation at moderate body composition.
- You are pregnant or planning pregnancy. GLP-1s are contraindicated in pregnancy and the platforms in this guide will not prescribe to pregnant patients. Buyers planning pregnancy within 12 months should defer GLP-1 supplementation until after the postpartum window, and buyers who become pregnant on a GLP-1 should discontinue immediately and contact their prescriber.
- You have a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. This is a hard contraindication for GLP-1 receptor agonists per the FDA black-box warning. The platforms in this guide will screen for this on the eligibility evaluation, but buyers with a known history should not pursue GLP-1 supplementation through telehealth or any other channel without specialist endocrinology consultation first.
- You have a history of pancreatitis or active gallbladder disease. GLP-1s elevate the risk of pancreatitis and gallbladder disease. Buyers with prior pancreatitis episodes or active gallbladder disease should run the decision through a specialist, not a telehealth eligibility evaluation. The platforms will screen for major risk factors but the risk-benefit math at the individual level requires specialist input.
- Your insurance covers branded Wegovy or Zepbound. If your plan covers the branded product at a copay you can absorb, that is the cheaper and safer path. Branded supply has more rigorous quality control than compounded supply, and the cost-savings argument for compounded telehealth disappears when insurance is paying for branded retail. Run the prior-authorization process with your primary care first; only fall back to telehealth compounded supply if insurance coverage is unavailable.
- You have not addressed the foundational stack first. GLP-1s are a metabolic-aging intervention layered on top of foundational health behaviors. Buyers who have not addressed sleep quality, dietary protein adequacy, exercise volume, and resistance training are pricing in expensive medication on top of structural gaps that are cheaper and lower-risk to fix first. The right sequence is foundational stack first, comprehensive bloodwork second (see our best diagnostic platform guide), and pharmacological intervention third — not the reverse.
The decision framework
Three questions decide the right GLP-1 telehealth platform for most buyers:
- Compounded or branded? If your insurance covers branded Wegovy or Zepbound, run that through your primary care first — it is the cheaper and safer path. If insurance is unavailable and you are paying cash, compounded supply at $175-300/month vs branded retail at $1,000-1,400/month is the entire reason this category exists. The compounded providers in this guide (bmiMD, Henry Meds, ShedRX, Levity) are the right fit for cash-pay buyers; Hims is the right fit for buyers who want telehealth convenience but prefer branded sourcing.
- Semaglutide-only or both molecules? If you are starting on Semaglutide and reasonably confident you will not need to step up to Tirzepatide, Levity offers the lowest entry economics ($175-225/mo) and is hard to beat on cost. If you anticipate needing Tirzepatide either now or within 12 months, picking a platform that covers both compounded molecules (bmiMD, ShedRX, Henry Meds) avoids the platform-switching tax of moving providers mid-protocol.
- Value-tier or ecosystem-mature? bmiMD and Levity are the value-tier picks with the lowest entry pricing on Semaglutide and Tirzepatide respectively. Henry Meds is the ecosystem-mature pick with the longest operational track record, broader pharmacy partner network, and the platform most likely to weather 2026-2027 regulatory changes intact. ShedRX is the multi-format pick for buyers who want non-injectable delivery options. Hims is the branded-supply pick post-March 2026 settlement. Pick the dimension that maps to your priority — cost, track record, format flexibility, or sourcing — and the platform follows.
If you're a value-tier buyer ready to start a compounded GLP-1 protocol with included physician oversight, buy bmiMD at $289/month for Semaglutide ($379.99 in CA/NC) or $349-399/month for Tirzepatide. If you weight ecosystem maturity over the $10-50 monthly delta, Henry Meds at $297/month Semaglutide and $449/month Tirzepatide is the longer-track-record alternative. If you want branded retail-grade access with telehealth convenience, Hims at $299/month branded Wegovy and $399/month branded Zepbound is the post-settlement default. If you specifically want compounded Tirzepatide value or non-injectable delivery formats, ShedRX at $275-375/month Tirzepatide or $199-229/month sublingual is the right call. If you want the lowest-entry compounded Semaglutide and don't anticipate needing Tirzepatide, Levity at $175-225/month is hard to beat. Pair any of these with a foundational diagnostic platform — see our best diagnostic platform guide for biomarker tracking — and remember that GLP-1 side effects are real and physician oversight is non-negotiable.
GLP-1 telehealth buyer's questions
Compounded vs branded — what is the difference?
Compounded GLP-1s contain the same active ingredient (Semaglutide or Tirzepatide) as branded Wegovy, Ozempic, Mounjaro, or Zepbound, but are mixed by a state-licensed compounding pharmacy rather than manufactured by Novo Nordisk or Eli Lilly. The cost gap is large — compounded Semaglutide runs roughly $175-300/month vs $1,000-1,400/month for branded retail. The legal basis for compounded GLP-1 supply was the FDA shortage list designation that began in 2022; that shortage status was resolved in 2024-2025, and the regulatory ground beneath compounded supply has been narrowing since. As of mid-2026, some platforms (notably Hims) have exited compounded Semaglutide following settlement with Novo Nordisk and now default new patients to branded products. Compounded supply continues at other platforms but the long-term trajectory is uncertain. The active ingredient is the same molecule; the regulatory framework, sourcing chain, and quality-control model are not.
Will my insurance cover this?
Generally no for the platforms in this guide. bmiMD, Henry Meds, Hims, ShedRX, and Levity all operate cash-pay outside the insurance system — the membership pricing reflects the all-in monthly cost (medication + physician oversight + shipping). Some buyers can run branded Wegovy or Zepbound through insurance separately if they meet BMI and metabolic criteria, but coverage decisions vary widely by plan and the prior-authorization process is meaningful friction. HSA/FSA reimbursement is generally available across all five platforms — bmiMD, Henry Meds, ShedRX, and Levity all explicitly accept HSA/FSA cards. The honest framing: GLP-1 telehealth is out-of-pocket spending, and the cost-savings argument vs branded retail is the entire reason the category exists. If your insurance covers branded retail, that is the cheaper path; if it does not, telehealth compounded supply is the alternative.
How long do you stay on GLP-1?
There is no universal answer. The clinical literature shows that weight regain after GLP-1 discontinuation is common — most patients regain 50-70% of lost weight within 12 months of stopping, in the absence of significant lifestyle change layered on top. That has driven the consensus that GLP-1s are typically a multi-year intervention rather than a short-term cycle, with some patients staying on them indefinitely (similar to a chronic-disease medication model) and others using them as a 6-18 month catalyst paired with sustained dietary and exercise change to maintain results post-discontinuation. The right duration depends on your starting BMI, metabolic risk profile, and behavioral capacity to sustain the protocol shifts the medication catalyzes. This is a conversation to have with your prescriber, not a decision to make off a guide.
What are the side effects?
Real for most users in the first 4-8 weeks. The most common side effects across both Semaglutide and Tirzepatide are gastrointestinal: nausea (most common, 15-30% of users), constipation, diarrhea, vomiting, and abdominal pain. Most resolve as the body adjusts and as titration ramps up gradually. Less common but more serious risks include pancreatitis, gallbladder disease, kidney injury (typically secondary to dehydration from prolonged GI symptoms), and a contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. The platforms in this guide all titrate doses (start low, increase over weeks) specifically to minimize the GI side effects. Buyers should plan for a tolerable but uncomfortable first month and have a clear escalation path with their prescriber if symptoms persist past week 4-6.
Is compounded as effective as Wegovy?
The active ingredient is the same molecule, so the pharmacology is identical at equivalent doses. The variability is in the formulation, sourcing chain, and quality control of the specific compounding pharmacy a platform uses. State-licensed 503A compounding pharmacies follow USP standards but quality varies — buyers cannot directly inspect the chain. Reputable platforms partner with 503B outsourcing facilities (which face more rigorous FDA oversight than 503A) and publish their pharmacy partners. Independent third-party testing of compounded GLP-1s has historically shown most pass quality assays, but a meaningful minority have shown potency variation or contamination issues. The pragmatic frame: compounded supply at established platforms is generally safe and effective, but the QC variance is a real consideration that branded retail does not have. If price is no object and your insurance covers branded retail, branded is the safer path.
What if I am in CA, NC, or another higher-pricing state?
Pricing varies meaningfully by state due to state-level pharmacy regulations, board-of-pharmacy rules, and partner-pharmacy availability. bmiMD explicitly notes CA and NC pricing is higher (Semaglutide $379.99/month in those states vs $289 elsewhere) — the platform is transparent about this in checkout. Other platforms have similar state-by-state pricing variation that may not surface until you complete the eligibility quiz. Buyers in CA, NC, NY, and a handful of other high-regulation states should expect to pay 20-30% more than the headline pricing across most providers. Some buyers in those states find the math closer to branded retail than the marketed compounded discount, which can shift the calculation toward running insurance through your primary care for branded supply instead.
Can I take peptides alongside?
Possibly, but not without prescriber coordination. The platforms in this guide are GLP-1-focused and typically do not prescribe other peptides. If you are running a peptide protocol (BPC-157, TB-500, growth hormone secretagogues, etc.) alongside GLP-1, you generally need a separate prescribing relationship with a peptide-friendly clinic — Marek Health and similar concierge providers are the typical path. The interaction risk is real for some combinations (e.g., GLP-1s slow gastric emptying, which can affect oral medication absorption timing). Buyers running multi-peptide stacks should ensure both prescribers know what the other is doing — splitting the prescribing relationship across platforms without coordination is the most common failure mode.
Tirzepatide vs Semaglutide — which to pick?
Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist; Semaglutide (Wegovy, Ozempic) is a GLP-1-only agonist. The dual-mechanism Tirzepatide has shown stronger weight-loss outcomes in head-to-head trials — the SURMOUNT and STEP trial families generally show Tirzepatide producing 18-22% body-weight loss at peak doses vs 14-17% for Semaglutide. The trade-off: Tirzepatide is meaningfully more expensive across the platforms in this guide ($349-449/month vs $199-297/month for compounded Semaglutide), and the longer-running clinical evidence base is on Semaglutide. For most buyers, the right framework is to start with Semaglutide if cost is a constraint and weight-loss target is moderate (10-15% body weight), and step up to Tirzepatide if Semaglutide response is insufficient or the weight-loss target is more aggressive (20%+ body weight). This decision should be made with your prescriber, not off a comparison table.
Are these FDA-approved?
The branded products (Wegovy, Ozempic, Mounjaro, Zepbound) are FDA-approved. The compounded products offered by most of these platforms are not FDA-approved as finished products — they are pharmacy-compounded under state-licensed compounding pharmacy regulations. The compounding-pharmacy model is legal under FDA rules, but the finished compounded product does not go through the same approval process as the branded retail. The FDA shortage-list mechanism that previously enabled large-scale compounded GLP-1 supply was resolved in 2024-2025, and FDA enforcement priorities around compounded supply have been shifting. Buyers should price in the regulatory uncertainty: compounded supply may face increased restrictions or platform exits in 2026-2027, similar to the Hims compounded-Semaglutide wind-down following the March 2026 Novo Nordisk settlement.
How does titration work?
GLP-1s are titrated up gradually to minimize GI side effects. The standard Semaglutide protocol starts at 0.25mg/week for the first 4 weeks, then 0.5mg/week for weeks 5-8, escalating to 1.0mg, 1.7mg, and finally 2.4mg/week as the maintenance dose for weight loss. Tirzepatide follows a similar pattern starting at 2.5mg/week and escalating in 2.5mg increments every 4 weeks up to a maximum of 15mg/week. The platforms in this guide manage titration through their physician-overseen protocols — your prescriber adjusts the dose based on tolerance and weight-loss response. Most buyers reach their target maintenance dose within 4-5 months of starting. Skipping titration steps is the most common cause of severe GI side effects, and the platforms generally do not let you fast-forward the schedule even if you tolerate the lower doses well.
Build the surrounding longevity stack
GLP-1 telehealth is one layer of a broader longevity stack. The other high-conviction layers most serious buyers run alongside metabolic-aging intervention:
- Best diagnostic platform 2026 — Mito Health, Function Health, InsideTracker, and Lifeforce compared. Comprehensive biomarker tracking is the data layer GLP-1 supplementation needs.
- Best NMN supplements 2026 — Wonderfeel, Renue by Science, Genuine Purity, and the Tru Niagen NR alternative for the NAD+ precursor layer.
- Best cold plunges 2026 — Plunge Pro, Renu, Edge, Inergize, Ice Barrel head-to-head.
- Best longevity wearables 2026 — Oura, WHOOP, Ultrahuman, Apple Watch, Garmin compared.
- Best infrared saunas 2026 — the hot-side complement to cold plunge.
- Best sleep tech 2026 — mattresses, climate control, and sleep-stage tooling.
This guide was researched and written by the editorial team at Lifespan Vault, sister publication to MyProtocolStack. Platform pricing, molecule coverage, physician oversight model, state availability, and money-back policies were verified against manufacturer pages and category trackers on 2026-05-05. Pricing is dated and may shift; we update verified-at dates on individual product pages quarterly. State-by-state pricing variation applies — buyers in CA, NC, NY, and other high-regulation states should expect 20-30% above headline pricing. Lifespan Vault may earn affiliate commission on outbound product links — bmiMD is the only platform in this guide where we currently have an active affiliate relationship (via Awin, $50 CPA, 30-day cookie). Henry Meds, Hims, ShedRX, and Levity are listed for editorial completeness with direct links and no commission. Rankings and editorial coverage are not for sale, and disclosures appear on every product page. Not medical advice. GLP-1 medications require physician oversight; see your prescriber before starting any protocol. For our full review process, see methodology / test protocol.